Impact of polyunsaturated fatty acid consumption prior to ischemic stroke

Acta Neurologica Scandinavica

Volumn 127, Issue 3, 2013, Pages 181-185

  Mishina, M ^a,b   Kim, K ^a   Kominami, S ^a   Mizunari, T ^a   Kobayashi, S ^a   Katayama, Y ^b  

^a NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Arachidonic acid; Atherothrombotic infarction; Cardiogenic embolism; Dihomo linolenic acid; Docosahexaenoic acid; Eicosapentaenoic acid; Lacunar infarction; Severity

Indexed keywords

ARACHIDONIC ACID; DIHOMO GAMMA LINOLENIC ACID; DOCOSAHEXAENOIC ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LINOLENIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL; URIC ACID;

AGED; ARTICLE; BRAIN ISCHEMIA; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; DIET RESTRICTION; DISEASE SEVERITY; EATING HABIT; EMBOLISM; FAT INTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL DISCHARGE; HUMAN; LACUNAR STROKE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; STROKE PATIENT; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DIET; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; STROKE;

EID: 84873988275     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2012.01695.x     Document Type: Article

References (38)

1. Sandset EC, Bath PM, Boysen G et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011;377:741-50.
2. Amarenco P, Goldstein LB, Callahan A, 3rd. et al. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis 2009;204:515-20.
3. O'regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121, 000 patients. Am J Med 2008;121:24-33.
4. Vauthey C, De Freitas GR, Van Melle G, Devuyst G, Bogousslavsky J. Better outcome after stroke with higher serum cholesterol levels. Neurology 2000;54:1944-9.
5. Olsen TS, Christensen RH, Kammersgaard LP, Andersen KK. Higher total serum cholesterol levels are associated with less severe strokes and lower all-cause mortality: ten-year follow-up of ischemic strokes in the Copenhagen Stroke Study. Stroke 2007;38:2646-51.
6. Bang OY, Saver JL, Liebeskind DS et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology 2007;68:737-42.
7. Mishina M, Komaba Y, Kobayashi S et al. Administration of free radical scavenger edaravone associated with higher frequency of hemorrhagic transformation in patients with cardiogenic embolism. Neurol Med Chir 2008;48:292-7.
8. Ramirez-Moreno JM, Casado-Naranjo I, Portilla JC et al. Serum cholesterol LDL and 90-day mortality in patients with intracerebral hemorrhage. Stroke 2009;40:1917-20.
9. Zhang X, Patel A, Horibe H et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003;32:563-72.
10. Zhang J, Sasaki S, Amano K, Kesteloot H. Fish consumption and mortality from all causes, ischemic heart disease, and stroke: an ecological study. Prev Med 1999;28:520-9.
11. Iso H, Sato S, Folsom AR et al. Serum fatty acids and fish intake in rural Japanese, urban Japanese, Japanese American and Caucasian American men. Int J Epidemiol 1989;18:374-81.
12. Sekikawa A, Curb JD, Ueshima H et al. Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol 2008;52:417-24.
13. Morris MC, Evans DA, Bienias JL et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003;60:940-6.
14. Yokoyama M, Origasa H. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Am Heart J 2003;146:613-20.
15. Yokoyama M, Origasa H, Matsuzaki M et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8.
16. Tanaka K, Ishikawa Y, Yokoyama M et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke 2008;39:2052-8.
17. Adams HP, Jr., Bendixen BH, Kappelle LJ et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
18. Lee LJ, Kidwell CS, Alger J, Starkman S, Saver JL. Impact on stroke subtype diagnosis of early diffusion-weighted magnetic resonance imaging and magnetic resonance angiography. Stroke 2000;31:1081-9.
19. Ishiguro J, Tada T, Ogihara T, Ohzawa N, Murakami K, Kosuzume H. Metabolic disposition of ethyl eicosapentaenoate and its metabolites in rats and dogs. J Pharmacobiodyn 1988;11:251-61.
20. Hirai A, Hamazaki T, Terano T et al. Eicosapentaenoic acid and platelet function in Japanese. Lancet 1980;2:1132-3.
21. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, Van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-7.
22. Okuda Y, Mizutani M, Ogawa M et al. Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus. J Diabetes Complications 1996;10:280-7.
23. Liebich HM, Wirth C, Jakober B. Analysis of polyunsaturated fatty acids in blood serum after fish oil administration. J Chromatogr 1991;572:1-9.
24. Katayama Y, Katsumata T, Muramatsu H, Usuda K, Obo R, Terashi A. Effect of long-term administration of ethyl eicosapentate (EPA-E) on local cerebral blood flow and glucose utilization in stroke-prone spontaneously hypertensive rats (SHRSP). Brain Res 1997;761:300-5.
25. Katsumata T, Katayama Y, Obo R, Muramatsu H, Ohtori T, Terashi A. Delayed administration of ethyl eicosapentate improves local cerebral blood flow and metabolism without affecting infarct volumes in the rat focal ischemic model. Eur J Pharmacol 1999;372:167-74.
26. Yoneda H, Shirao S, Kurokawa T, Fujisawa H, Kato S, Suzuki M. Does eicosapentaenoic acid (EPA) inhibit cerebral vasospasm in patients after aneurysmal subarachnoid hemorrhage? Acta Neurol Scand 2008;118:54-9.
27. Belayev L, Khoutorova L, Atkins KD et al. Docosahexaenoic Acid Therapy of Experimental Ischemic Stroke. Transl Stroke Res 2011;2:33-41.
28. Tan ZS, Harris WS, Beiser AS et al. Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging. Neurology 2012;78:658-64.
29. Breslow JL. n-3 fatty acids and cardiovascular disease. Am J Clin Nutr 2006;83:1477S-82S.
30. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006;296:1885-99.
31. Bernstein AM, Ding EL, Willett WC, Rimm EB. A meta-analysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease. J Nutr 2012;142:99-104.
32. Hersher R. Are drugmakers fishing for a market with prescription omega-3s? Nat Med 2012;18:6.
33. Takai S, Jin D, Kawashima H et al. Anti-atherosclerotic effects of dihomo-gamma-linolenic acid in ApoE-deficient mice. J Atheroscler Thromb 2009;16:480-9.
34. Dooper MM, Wassink L, M'rabet L, Graus YM. The modulatory effects of prostaglandin-E on cytokine production by human peripheral blood mononuclear cells are independent of the prostaglandin subtype. Immunology 2002;107:152-9.
35. Johnson MM, Swan DD, Surette ME et al. Dietary supplementation with gamma-linolenic acid alters fatty acid content and eicosanoid production in healthy humans. J Nutr 1997;127:1435-44.
36. Wright S, Burton JL. Oral evening-primrose-seed oil improves atopic eczema. Lancet 1982;2:1120-2.
37. Henz BM, Jablonska S, Van Dekerkhof PC et al. Double-blind, multicentre analysis of the efficacy of borage oil in patients with atopic eczema. Br J Dermatol 1999;140:685-8.
38. Teraoka N, Kawashima H, Shiraishi-Tateishi A et al. Oral supplementation with dihomo-gamma-linolenic acid-enriched oil altered serum fatty acids in healthy men. Biosci Biotechnol Biochem 2009;73:1453-5.